Vaccine Adverse Event Reporting System (VAERS) - Allie: Abbreviation / Long Form Info.

■ Abbreviation / Long Form : VAERS / Vaccine Adverse Event Reporting System

[Related PubMed/MEDLINE]
Total Number of Papers: 401

[Display Entries]

>> all entries

[Entries Per Page]

per page

Page Control

Page: of

Abbreviation:	VAERS (>> Co-occurring Abbreviation)
Long Form:	Vaccine Adverse Event Reporting System

Abbreviation Variation

Long Form Variation

Vaccine Adverse Event Reporting System (379 times)

Vaccine Adverse Events Reporting System (46 times)

vaccine adverse event reporting system (30 times)

vaccine adverse events reporting system (4 times)

Vaccine adverse event reporting system (2 times)

Vaccine Adverse Event Report System (2 times)

Vaccine AE Reporting System (2 times)

Vaccine Adverse Event reporting System (2 times)

Vaccine Adverse Event Reporting system (2 times)

Vaccination Adverse Event Reporting System (1 time)

Vaccine Adverse a fall Event Reporting System (1 time)

Vaccine Adverse Effect Reporting System (1 time)

Vaccine Adverse Event-Reporting System (1 time)

Vaccine Adverse Reporting System (1 time)

Vaccine Adverse Events Report System (1 time)

Vaccines Adverse Event Reporting System (1 time)

Vaccine-Adverse Event-Reporting System (1 time)

Pair(Abbreviation/Long Form) Variation

			VAERS / Vaccine Adverse Event Reporting System (379 times)
			VAERS / Vaccine Adverse Events Reporting System (46 times)
			VAERS / vaccine adverse event reporting system (30 times)
			VAERS / vaccine adverse events reporting system (4 times)
			VAERS / Vaccine AE Reporting System (2 times)
			VAERS / Vaccine Adverse Event Report System (2 times)
			VAERS / Vaccine Adverse Event Reporting system (2 times)
			VAERS / Vaccine Adverse Event reporting System (2 times)
			VAERS / Vaccine adverse event reporting system (2 times)
			VAERS / Vaccine Adverse Events Report System (1 time)
			VAERS / Vaccine Adverse a fall Event Reporting System (1 time)
			VAERS / Vaccine Adverse Reporting System (1 time)
			VAERS / Vaccine Adverse Effect Reporting System (1 time)
			VAERS / Vaccination Adverse Event Reporting System (1 time)
			VAERS / Vaccine-Adverse Event-Reporting System (1 time)
			VAERS / Vaccines Adverse Event Reporting System (1 time)
			VAERS / Vaccine Adverse Event-Reporting System (1 time)

No.	Year	Title	Co-occurring Abbreviation
1	2023	Analysis of hematologic adverse events reported to a national surveillance system following COVID-19 bivalent booster vaccination.	AIHA, ITP, SARS-CoV-2, VITT
2	2023	Automatic Identification of Self-Reported COVID-19 Vaccine Information from Vaccine Adverse Events Reporting System.	COVID-19, GS, NLP
3	2023	COVID-19 Vaccine Safety First Year Findings in Adolescents.	---
4	2023	Death and Disability Reported with Cases of Vaccine Anaphylaxis Stratified by Administration Setting: An Analysis of the Vaccine Adverse Event Reporting System from 2017 to 2022.	CI
5	2023	Herpetic Eye Disease After SARS-CoV-2 Vaccination: A CDC-VAERS Database Analysis.	CDC, HSO, HZO
6	2023	Mining adverse events in large frequency tables with ontology, with an application to the vaccine adverse event reporting system.	AE
7	2023	Post-vaccination headache reporting: Trends according to the Vaccine Adverse Events Reporting System.	---
8	2023	Real-life safety profile of mRNA vaccines for COVID-19: An analysis of VAERS database.	CI
9	2023	Reported rates of all-cause serious adverse events following immunization with BNT-162b in 5-17-year-old children in the United States.	RSV, sAEFI, US
10	2023	Reporting rates for VAERS death reports following COVID-19 vaccination, December 14, 2020-November 17, 2021.	---
11	2023	Reports of Guillain-Barré Syndrome After COVID-19 Vaccination in the United States.	GBS, OE, RRRs
12	2023	Reports of Guillain-Barre Syndrome Following COVID-19 Vaccination in the USA: An Analysis of the VAERS Database.	GBS/V, IQR
13	2023	Safety Monitoring of Bivalent COVID-19 mRNA Vaccine Booster Doses Among Children Aged 5-11 Years - United States, October 12-January 1, 2023.	ACIP, EUAs, FDA
14	2023	Safety of co-administration of mRNA COVID-19 and seasonal inactivated influenza vaccines in the vaccine adverse event reporting system (VAERS) during July 1, 2021-June 30, 2022.	AEs, AESI, PTs
15	2023	Safety of COVID-19 vaccines in pregnancy: a VAERS based analysis.	AEFIs
16	2023	Spontaneous reports of primary ovarian insufficiency after vaccination: A review of the vaccine adverse event reporting system (VAERS).	ACOG, HPV, POI
17	2023	Vaccine adverse event reporting system (VAERS): Evaluation of 31 years of reports and pandemics' impact.	AEFIs, COVID-19, US
18	2022	A Case Report of Sudden Sensorineural Hearing Loss (SSNHL) After Administration of the COVID-19 Vaccine.	COVID-19, EUA, SSNHL, US
19	2022	A Comparative Analysis of COVID-19 Vaccines Based on over 580,000 Cases from the Vaccination Adverse Event Reporting System.	ORs
20	2022	A Possible Case of COVID-19 Booster Vaccine-Associated Rhabdomyolysis and Acute Kidney Injury.	ADRs, COVID-19, GBS, mRNA, SARS-CoV-2, TTS
21	2022	Acute kidney injury after COVID-19 vaccines: a real-world study.	AKI, COVID-19
22	2022	Adverse Events and Safety Profile of the COVID-19 Vaccines in Adolescents: Safety Monitoring for Adverse Events Using Real-World Data.	AEs
23	2022	Analyses of reported severe adverse events after immunization with SARS-CoV-2 vaccines in the United States: One year on.	ED, IRRs, sAEFI, US
24	2022	Analyzing the U.S. Post-marketing safety surveillance of COVID-19 vaccines.	AEs, PMS, US
25	2022	Assessment of Sudden Sensorineural Hearing Loss After COVID-19 Vaccination.	SSNHL
26	2022	Association between seasonal influenza vaccines and the increased risk of acute disseminated encephalomyelitis, estimated using the Vaccine Adverse Event Reporting System.	ADEM, Cell-based vaccine, CNS, Egg-based vaccine, ROR, WSPs
27	2022	Autoimmune haemolytic anaemia and immune thrombocytopenia following SARS-CoV-2 and non-SARS-CoV-2 vaccination: 32 Years of passive surveillance data.	AIHA, CDC, ITP, MMR
28	2022	BNT162b2 Vaccine-Associated Myo/Pericarditis in Adolescents: A Stratified Risk-Benefit Analysis.	---
29	2022	Booster dose of COVID-19 mRNA vaccine does not increase risks of myocarditis and pericarditis compared with primary vaccination: New insights from the vaccine adverse event reporting system.	CDC
30	2022	Characteristics and Comparison of Adverse Events of Coronavirus Disease 2019 Vaccines Reported to the United States Vaccine Adverse Event Reporting System Between 14 December 2020 and 8 October 2021.	AEs, COVID-19, ER, RORs
31	2022	Coagulation factor inhibitors in COVID-19: From SARS-CoV-2 vaccination to infection.	SARS-CoV-2
32	2022	Comparability of clinical trials and spontaneous reporting data regarding COVID-19 vaccine safety.	AEs, RCTs
33	2022	Comparison of the post-marketing safety profile between influenza and COVID-19 vaccines: An analysis of the vaccine adverse event reporting system.	AEs
34	2022	COVID-19 Vaccination a Cause of Guillain-Barre Syndrome? A Case Series.	GBS
35	2022	COVID-19 vaccine and menstrual conditions in female: data analysis of the Vaccine Adverse Event Reporting System (VAERS).	COVID-19, ROR
36	2022	COVID-19 Vaccine as a Potential Triggering Factor for Anti-Glomerular Basement Membrane (GBM) Disease: A Case Report and Literature Review.	Anti-GBM, GBM, RPGN
37	2022	Curbing COVID-19 Vaccine Hesitancy from a Dermatological Standpoint: Analysis of Cutaneous Reactions in the Vaccine Adverse Event Reporting System (VAERS) Database.	---
38	2022	Disentangling a Thorny Issue: Myocarditis and Pericarditis Post COVID-19 and Following mRNA COVID-19 Vaccines.	---
39	2022	Frequency and Associations of Adverse Reactions of COVID-19 Vaccines Reported to Pharmacovigilance Systems in the European Union and the United States.	CTC
40	2022	Glaucoma Cases Following SARS-CoV-2 Vaccination: A VAERS Database Analysis.	SARS-CoV-2
41	2022	Hearing disorder following COVID-19 vaccination: A pharmacovigilance analysis using the Vaccine Adverse Event Reporting System.	CI, COVID-19, PRR, ROR
42	2022	Herpes zoster and simplex reactivation following COVID-19 vaccination: new insights from a vaccine adverse event reporting system (VAERS) database analysis.	---
43	2022	Modeling COVID-19 Vaccine Adverse Effects with a Visualized Knowledge Graph Database.	---
44	2022	Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021.	---
45	2022	Neurological Events Reported after COVID-19 Vaccines: An Analysis of VAERS.	CVT, GBS
46	2022	OAE-based data mining and modeling analysis of adverse events associated with three licensed HPV vaccines.	AEs, GPS, HPV, OAE, SAEs
47	2022	Ocular Complications after COVID-19 Vaccination, Vaccine Adverse Event Reporting System.	---
48	2022	Oral Adverse Events Following COVID-19 Vaccination: Analysis of VAERS Reports.	AEs
49	2022	Pediatric COVID-19 Vaccination: A Description of Adverse Events or Reactions Reported in Kansans Aged 6 to 17.	AERs
50	2022	Post-authorization surveillance of adverse events following COVID-19 vaccines in pregnant persons in the vaccine adverse event reporting system (VAERS), December 2020 - October 2021.	AEs
51	2022	Posterior Reversible Encephalopathy Syndrome Onset Within 24 Hours Following Moderna mRNA Booster COVID-19 Vaccination: Vaccine Adverse Event Vs. Hypertension?	COVID-19, PRES, SARS-CoV-2
52	2022	Postmarketing safety surveillance of high-dose quadrivalent influenza vaccine: Reports to the Vaccine Adverse Event Reporting System.	---
53	2022	Profiling COVID-19 Vaccine Adverse Events by Statistical and Ontological Analysis of VAERS Case Reports.	AEs, OAE, TTS
54	2022	Prolonged Diarrhea Following COVID-19 Vaccination: A Case Report and Literature Review.	COVID-19, CT, SARS-CoV-2
55	2022	Psychotropic drugs interaction with the lipid nanoparticle of COVID-19 mRNA therapeutics.	mRNA, SPI
56	2022	Reply to: correspondence on "Herpes Zoster and Simplex reactivation following COVID-19 vaccination: new insights from a vaccine adverse event reporting system (VAERS) database analysis".	---
57	2022	Reports of myocarditis and pericarditis following mRNA COVID-19 vaccination: a systematic review of spontaneously reported data from the UK, Europe and the USA and of the scientific literature.	EU/EEA, mRNA
58	2022	Risk Factors and Incidence Rates of Self-Reported Short-Term Adverse Events of COVID-19 Vaccine Booster Dose.	AE, IR, NSAE, SAE
59	2022	Risk of Myocarditis and Pericarditis among Young Adults following mRNA COVID-19 Vaccinations.	---
60	2022	Safety Monitoring of Bivalent COVID-19 mRNA Vaccine Booster Doses Among Persons Aged ≥12 Years - United States, August 31-October 23, 2022.	ACIP, FDA
61	2022	Safety Monitoring of COVID-19 mRNA Vaccine First Booster Doses Among Persons Aged ≥12 Years with Presumed Immunocompromise Status - United States, January 12, 2022-March 28, 2022.	ACIP, FDA
62	2022	Safety Monitoring of COVID-19 mRNA Vaccine Second Booster Doses Among Adults Aged ≥50 Years - United States, March 29, 2022-July 10, 2022.	ACIP, FDA
63	2022	Safety Monitoring of COVID-19 Vaccine Booster Doses Among Adults - United States, September 22, 2021-February 6, 2022.	ACIP, FDA
64	2022	Safety Monitoring of COVID-19 Vaccine Booster Doses Among Persons Aged 12-17 Years - United States, December 9, 2021-February 20, 2022.	EUA, FDA
65	2022	Safety Monitoring of JYNNEOS Vaccine During the 2022 Mpox Outbreak - United States, May 22-October 21, 2022.	eIND, EUA, FDA, mpox, VSD
66	2022	Safety Monitoring of Pfizer-BioNTech COVID-19 Vaccine Booster Doses Among Children Aged 5-11 Years - United States, May 17-July 31, 2022.	EUA, FDA
67	2022	Safety of Booster Doses of Coronavirus Disease 2019 (COVID-19) Vaccine in Pregnancy in the Vaccine Adverse Event Reporting System.	COVID-19
68	2022	Safety of COVID-19 Vaccination in United States Children Ages 5 to 11 Years.	---
69	2022	Safety of mRNA vaccines administered during the initial 6 months of the US COVID-19 vaccination programme: an observational study of reports to the Vaccine Adverse Event Reporting System and v-safe.	---
70	2022	Safety Surveillance of Varicella Vaccines in the Vaccine Adverse Event Reporting System, United States, 2006-2020.	AEs, MMRV, VAR
71	2022	SARS-CoV-2 vaccine-associated-tinnitus: A review.	---
72	2022	Serious adverse reaction associated with the COVID-19 vaccines of BNT162b2, Ad26.COV2.S, and mRNA-1273: Gaining insight through the VAERS.	AEFI, ROR, TTO
73	2022	Shoulder injury related to vaccine administration (SIRVA) after COVID-19 vaccination.	SIRVA
74	2022	Spread of COVID-19 Vaccine Misinformation in the Ninth Inning: Retrospective Observational Infodemic Study.	---
75	2022	Symptomatic Myocarditis Post COVID-19 Vaccination.	COVID-19, mRNA
76	2022	Systematic review of spontaneous reports of myocarditis and pericarditis in transplant recipients and immunocompromised patients following COVID-19 mRNA vaccination.	EU/EEA, PRR
77	2022	The COVID-19 Vaccines: A Description of Adverse Events of Reactions Reported in Kansas.	AERs, COVID-19, SARS-CoV-2
78	2022	The Safety of mRNA-1273, BNT162b2 and JNJ-78436735 COVID-19 Vaccines: Safety Monitoring for Adverse Events Using Real-World Data.	AEs
79	2022	Thromboembolic events after Ad.26.COV2.S COVID-19 vaccine: Reports to the Vaccine Adverse Event Reporting System.	FDA, TEEs
80	2022	Transient Myopericarditis Following Vaccination for COVID-19.	CDC, mRNA, SARS-CoV-2
81	2022	Trends in reporting embolic and thrombotic events after COVID-19 vaccination: A retrospective, pharmacovigilance study.	COVID-19, ETEs, ROR
82	2022	Uncommon Side Effects of COVID-19 Vaccination in the Pediatric Population.	CDC, COVID-19, MIS-C
83	2022	Use of the Janssen (Johnson & Johnson) COVID-19 Vaccine: Updated Interim Recommendations from the Advisory Committee on Immunization Practices - United States, December 2021.	ACIP, CVST, EUA, FDA, GBS, TTS
84	2022	Usefulness of Vaccine Adverse Event Reporting System for Machine-Learning Based Vaccine Research: A Case Study for COVID-19 Vaccines.	---
85	2021	A Rare Variant of Guillain-Barre Syndrome Following Ad26.COV2.S Vaccination.	COVID-19, FDA, GBS, SARS-CoV-2
86	2021	Acute Myocardial Injury Following COVID-19 Vaccination: A Case Report and Review of Current Evidence from Vaccine Adverse Events Reporting System Database.	---
87	2021	Age and Gender Disparities in Adverse Events Following COVID-19 Vaccination: Real-World Evidence Based on Big Data for Risk Management.	AEs, COVID-19, ER
88	2021	Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Moderna COVID-19 Vaccine - United States, December 21, 2020-January 10, 2021.	ACIP, COVID-19, EUA, FDA
89	2021	Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine - United States, December 14-23, 2020.	ACIP, COVID-19, EUA, FDA
90	2021	Anxiety-Related Adverse Event Clusters After Janssen COVID-19 Vaccination - Five U.S. Mass Vaccination Sites, April 2021.	EUA, FDA
91	2021	Association of Receipt of the Ad26.COV2.S COVID-19 Vaccine With Presumptive Guillain-Barre Syndrome, February-July 2021.	FDA, GBS
92	2021	COVID-19 mRNA Vaccines Are Generally Safe in the Short Term: A Vaccine Vigilance Real-World Study Says.	AEFIs
93	2021	COVID-19 Vaccine Safety in Adolescents Aged 12-17 Years - United States, December 14, 2020-July 16, 2021.	ACIP, EUA, FDA
94	2021	COVID-19 Vaccine Safety in Children Aged 5-11 Years - United States, November 3-December 19, 2021.	ACIP, EUA, FDA
95	2021	Editorial: What Can be Learned from National and International Vaccine Adverse Event Reporting Systems During the COVID-19 Pandemic?	CDC, FDA
96	2021	Evaluaton of adverse events following immunization reported during national immunization programs (Between 2017-2019 in Ankara Province).	AEFI, EPI
97	2021	Extracting postmarketing adverse events from safety reports in the vaccine adverse event reporting system (VAERS) using deep learning.	AEs, BERT, GBS
98	2021	Facial nerve palsy following the administration of COVID-19 mRNA vaccines: analysis of a self-reporting database.	AEFI, CI, COVID-19, ROR
99	2021	Facial paralysis and vaccinations: a vaccine adverse event reporting system review.	---
100	2021	First Month of COVID-19 Vaccine Safety Monitoring - United States, December 14, 2020-January 13, 2021.	COVID-19, EUA, FDA, LTCF